Eli Lilly has posted a 7% decline in net income for the third quarter of2001 to $723.2 million, or $0.66 per share, noting that these figures exclude one-time events such as early debt retirement, restructuring and acquisitions. If these sums are taken into account, net income fell 27%.
Sales for the reporting period were up just 2% to $2.87 billion as the loss of patent protection on the antidepressant Prozac (fluoxetine) took effect. Combined sales of Prozac and the line extension Sarafem (also fluoxetine) decreased 34% to $449.4 million and were down 43% to $335.7 million in the USA as generic competition entered the market.
Zyprexa now lead product
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze